MOUNTAIN VIEW, Calif.,
April 27, 2016 /PRNewswire/
-- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, "Alexza", or
the "Company") will report results for its fiscal quarter ended
March 31, 2016 on Wednesday, May 11, 2016, following the close of
the U.S. financial markets. The Company will also host an
investor conference call and live webcast on the same day at
5:00 p.m. Eastern Time to provide a
company update and discuss the financial results.
Conference Call Information - 5:00 p.m.
Eastern Time on May 11,
2016
To access the webcast via the Internet, go to www.alexza.com, under
the "Investors" link. Please log onto the webcast prior to
the start of the call to ensure time for any software downloads
that may be required to participate in the webcast.
LIVE CALL:
1-844-492-3732 or +1-412-542-4199
(international)
Passcode: Please ask to be joined into the Alexza
Pharmaceuticals call.
REPLAY:
1-877-344-7529 or +1-412-317-0088
(international)
Passcode: 10084678
A replay of the conference call may also be accessed at
www.alexza.com under the "Investors" link. A replay of the
call will be available for 7 days following the conference
call.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development, and
commercialization of novel, proprietary products for the acute
treatment of central nervous system conditions.
Alexza's products and development pipeline are based on the
Staccato® system, a hand-held inhaler designed to
deliver a pure drug aerosol to the deep lung, providing rapid
systemic delivery and therapeutic onset, in a simple, non-invasive
manner. Active pipeline product candidates include AZ-002
(Staccato alprazolam) for the management of epilepsy in
patients with acute repetitive seizures and AZ-007 (Staccato
zaleplon) for the treatment of patients with middle of the night
insomnia.
ADASUVE® is Alexza's first commercial product.
ADASUVE is approved for marketing in 42 countries and has been
submitted for approval in seven additional countries. ADASUVE
has been launched and is currently available in 20 countries.
Grupo Ferrer Internacional SA ("Ferrer") is Alexza's commercial
partner for ADASUVE in Europe,
Latin America, the Commonwealth of
Independent States countries, the Middle
East and North Africa
countries, Korea, the Philippines
and Thailand.
ADASUVE® and Staccato® are registered
trademarks of Alexza Pharmaceuticals, Inc. For more
information about Alexza, the Staccato system technology or
the Company's development programs, please visit
www.alexza.com.
Safe Harbor Statement
The anticipated news release
and conference call will contain forward-looking statements that
involve significant risks and uncertainties. Any statement
describing the Company's expectations or beliefs is a
forward-looking statement, as defined in the Private Securities
Litigation Reform Act of 1995, and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of
developing and commercializing drugs, including the Company's
ability to complete any potential acquisition or other strategic
transaction, the adequacy of the Company's capital to support the
Company's operations, the ability of Alexza and Ferrer to
effectively and profitably commercialize ADASUVE, Alexza's ability
to secure a new U.S. commercial partner for ADASUVE and the terms
of any such partnership, estimated product revenues and royalties
associated with the sale of ADASUVE, and the Company's ability to
raise additional funds and the potential terms of such potential
financings. The Company's forward-looking statements also
involve assumptions that, if they prove incorrect, would cause its
results to differ materially from those expressed or implied by
such forward-looking statements. These and other risks concerning
Alexza's business are described in additional detail in the
Company's Annual Report on Form 10-K for the year ended
December 31, 2015 and the Company's
other Periodic and Current Reports filed with the Securities and
Exchange Commission. Forward-looking statements contained in this
announcement are made as of this date, and the Company undertakes
no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Logo -
http://photos.prnewswire.com/prnh/20140121/SF49110LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/alexza-to-report-2016-first-quarter-financial-results-and-provide-corporate-update-on-wednesday-may-11-2016-300256914.html
SOURCE Alexza Pharmaceuticals, Inc.